In the past week, RGLS stock has gone down by -10.69%, with a monthly decline of -0.85% and a quarterly surge of 107.08%. The volatility ratio for the week is 8.74%, and the volatility levels for the last 30 days are 9.78% for Regulus Therapeutics Inc The simple moving average for the past 20 days is -13.13% for RGLS’s stock, with a 51.86% simple moving average for the past 200 days.
Is It Worth Investing in Regulus Therapeutics Inc (NASDAQ: RGLS) Right Now?
Additionally, the 36-month beta value for RGLS is 1.56. There are mixed opinions on the stock, with 0 analysts rating it as a “buy,” 1 rating it as “overweight,” 5 rating it as “hold,” and 0 rating it as “sell.”
The public float for RGLS is 57.42M and currently, short sellers hold a 9.45% ratio of that float. The average trading volume of RGLS on April 18, 2024 was 3.06M shares.
RGLS) stock’s latest price update
Regulus Therapeutics Inc (NASDAQ: RGLS)’s stock price has gone decline by -8.59 in comparison to its previous close of 2.56, however, the company has experienced a -10.69% decrease in its stock price over the last five trading days. Zacks Investment Research reported 2024-03-13 that Data from an early-stage study shows that treatment with Regulus’ (RGLS) lead drug shows increased biological activity at a higher dose in patients with autosomal dominant polycystic kidney disease.
Analysts’ Opinion of RGLS
Many brokerage firms have already submitted their reports for RGLS stocks, with Leerink Partners repeating the rating for RGLS by listing it as a “Outperform.” The predicted price for RGLS in the upcoming period, according to Leerink Partners is $6 based on the research report published on March 18, 2024 of the current year 2024.
B. Riley FBR Inc., on the other hand, stated in their research note that they expect to see RGLS reach a price target of $1. The rating they have provided for RGLS stocks is “Neutral” according to the report published on March 28th, 2018.
Leerink Partners gave a rating of “Outperform” to RGLS, setting the target price at $2 in the report published on January 05th of the previous year.
RGLS Trading at 14.31% from the 50-Day Moving Average
After a stumble in the market that brought RGLS to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -38.26% of loss for the given period.
Volatility was left at 9.78%, however, over the last 30 days, the volatility rate increased by 8.74%, as shares sank -1.89% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading +74.63% upper at present.
During the last 5 trading sessions, RGLS fell by -10.69%, which changed the moving average for the period of 200-days by +59.18% in comparison to the 20-day moving average, which settled at $2.69. In addition, Regulus Therapeutics Inc saw 82.81% in overturn over a single year, with a tendency to cut further gains.
Insider Trading
Reports are indicating that there were more than several insider trading activities at RGLS starting from Hagan Joseph P, who sale 14,580 shares at the price of $1.19 back on Jan 18 ’24. After this action, Hagan Joseph P now owns 57,112 shares of Regulus Therapeutics Inc, valued at $17,359 using the latest closing price.
CALSADA CRISPINA, the Chief Financial Officer of Regulus Therapeutics Inc, sale 5,468 shares at $1.19 during a trade that took place back on Jan 18 ’24, which means that CALSADA CRISPINA is holding 5,782 shares at $6,510 based on the most recent closing price.
Stock Fundamentals for RGLS
The total capital return value is set at -1.4. Equity return is now at value -110.27, with -77.55 for asset returns.
Based on Regulus Therapeutics Inc (RGLS), the company’s capital structure generated 0.13 points at debt to capital in total, while cash flow to debt ratio is standing at -8.63. The debt to equity ratio resting at 0.15. The interest coverage ratio of the stock is -94.27.
Currently, EBITDA for the company is -30.88 million with net debt to EBITDA at 0.69. The liquidity ratio also appears to be rather interesting for investors as it stands at 2.96.
Conclusion
In conclusion, Regulus Therapeutics Inc (RGLS) has seen mixed performance in recent times. Analysts have a mixed opinion on the stock, with some rating it as a “buy” and others rating it as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
